News

Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of Clinical Research

Strattmont Group2019-12-17T20:17:04-05:00

Rockville, MD, April 2, 2017 - Precision-Biologics Inc.

2016 ASCO Annual Meeting – A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).

Strattmont Group2019-12-05T09:21:39-05:00

VIEW THE POSTER

Precision Biologics to Present Combination Immunotherapy of a Novel NEO-Epitope Antibody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016

Strattmont Group2019-12-17T20:20:06-05:00

New Orleans. LA– April 17, 2016 — Precision Biologics, a clinical stage biotechnology company...

NCI Investigators Collaborate with Moonshoot 2020

Strattmont Group2016-03-18T21:36:12-04:00

https://twitter.com/nciresearchctr/status/694520668679962624

Precision Biologics Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer‎ Who Failed all Standard Therapy

Strattmont Group2019-12-17T20:21:45-05:00

Over 30% of patients who failed all standard chemo and antibody therapy remain alive after...

Precision Biologics, Announces Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI)

Strattmont Group2019-12-17T20:12:08-05:00

December 21, 2015 08:00 AM Eastern Standard Time WASHINGTON--(BUSINESS WIRE)-- Today Precision Biologics Inc,...

Beth Israel Deaconess Medical Center (BIDMC) Joins Precision Biologics as Collaborators on Phase 2B Pancreatic Cancer Trial

Strattmont Group2015-08-20T03:17:57-04:00

Precision Biologics is pleased to announce the addition of Beth Israel Deaconess (BIDMC)as a collaborator...

Dana-Farber/Harvard Cancer Center (DF/HCC) and Massachusetts General Hospital (MGH) Join Precision Biologics as Collaborators on Phase 2B Pancreatic Cancer Trial

Strattmont Group2015-06-18T14:55:55-04:00

Precision Biologics is pleased to announce the addition of Dana-Farber/Harvard Cancer Center (DF/HCC) and Massachusetts...